Pregabalin Capsule
Product Images NDC 71610-765

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-765). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 75 mg (71610 0765 30)

Label for Pregabalin 75 mg oral capsules by Aphena Pharma Solutions - Tennessee, LLC. The label indicates a package containing 30 capsules with NDC 71610-0765-30. Storage instructions specify 20-25 degrees Celsius. Manufacturer is Invagen Pharmaceuticals, Inc., packaged by Aphena Pharma, Cookeville, TN.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Pregabalincaps Fig01)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin dosed at 25 mg, 100 mg, and 200 mg three times a day, and placebo. The graph compares patient improvement across these dosage groups, with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 2 (Pregabalincaps Fig02)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. The graph shows two lines representing Pregabalin 100 mg taken three times a day and placebo, illustrating patient response across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalincaps Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, as well as placebo, illustrating patient improvements across increasing pain relief percentages.*

FDA Label Image

Figure 4 (Pregabalincaps Fig04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows decreasing percent of patients improved as the percent improvement in pain increases from 0 to 100 percent.*

FDA Label Image

Figure 5 (Pregabalincaps Fig05)

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with lines indicating patient improvement differences between the groups.*

FDA Label Image

Figure 6 (Pregabalincaps Fig06)

A bar chart comparing responder rates (%) across different doses of Pregabalin in two clinical studies, Study E1 and Study E3. Study E1 shows increasing responder rates with doses from 50 mg to 600 mg given twice daily (BID), while Study E3 compares placebo with 600 mg once (BID) and thrice daily (TID) dosing. The x-axis lists dose groups and number of participants; the y-axis shows responder rates up to 60%.*

FDA Label Image

Figure 7 (Pregabalincaps Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day. The graph compares four study groups labeled E1 BD, E2 TID, E3 BD, and E3 TID, with data points showing significant p-values indicating statistical results at various dose levels, including placebo at zero dose. The y-axis represents seizure reduction percentage, and the x-axis shows increasing dose levels up to 600 mg/day.*

FDA Label Image

Figure 8 (Pregabalincaps Fig08)

A line chart showing the percent of patients improved relative to percent improvement in pain from baseline for different daily doses of Pregabalin (300 mg, 450 mg, 600 mg) compared to placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percent of patients improved (0 to 100%). Different line styles distinguish the Pregabalin doses and placebo.*

FDA Label Image

Figure 9 (Pregabalincaps Fig09)

A Kaplan-Meier survival curve comparing Pregabalin versus placebo over 180 days, showing estimated percentage of subjects without LTR on the y-axis and days on the x-axis. Pregabalin-treated subjects maintain a higher estimated percentage without LTR compared to placebo throughout the study period.*

FDA Label Image

Figure 11 (Pregabalincaps Fig10)

A line graph showing percent of subjects improved from baseline to week 12 BOCF for Pregabalin 75 mg capsules versus placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. The solid line represents Pregabalin, and the dashed line represents placebo, indicating higher percent improvement for Pregabalin over placebo across the range.*

FDA Label Image

Figure 12 (Pregabalincaps Fig11)

A line graph comparing percent of subjects improved versus percent improvement from baseline to week 16 BOCF for Pregabalin and placebo. The x-axis shows percent improvement from 0 to 100%, and the y-axis shows percent of subjects improved from 0 to 100%. Pregabalin is represented by a solid line, placebo by a dotted line, with Pregabalin consistently showing higher percentages of subjects improved across improvement levels.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalincaps Formula)

A formula for calculating creatinine clearance (CLcr) based on age (years), weight (kg), and serum creatinine (mg/dL), with an adjustment factor of 0.85 for female patients. The equation is provided in a clear mathematical layout.*

FDA Label Image

Chemical Structure (Pregabalincaps Str)

Chemical structure of pregabalin showing its molecular arrangement with key functional groups including an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.